We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: obesity
MedXY News
EnglishTag

obesity

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Semaglutide for Secondary CVD Prevention: Evaluating the Price of Clinical Success
Cardiologycardiovascular diseaseCost-Effectiveness

Semaglutide for Secondary CVD Prevention: Evaluating the Price of Clinical Success

By MedXY|Feb 5, 2026

A simulation study reveals that while semaglutide significantly reduces cardiovascular events in adults with obesity, its current cost exceeds traditional cost-effectiveness thresholds, requiring an 18% price reduction for broader economic

GLP-1 Receptor Agonists Significantly Reduce Atrial Fibrillation Recurrence and Mortality Following Catheter Ablation in Obese Patients
Cardiologyatrial fibrillationcatheter ablation

GLP-1 Receptor Agonists Significantly Reduce Atrial Fibrillation Recurrence and Mortality Following Catheter Ablation in Obese Patients

By MedXY|Feb 4, 2026

This large-scale real-world analysis reveals that GLP-1 receptor agonist therapy reduces atrial fibrillation recurrence by 18% and lowers all-cause mortality in obese patients following catheter ablation, highlighting a potent upstream stra

GLP-1 Receptor Agonists Associated with Lower Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients
Cardiologyatrial fibrillationcatheter ablation

GLP-1 Receptor Agonists Associated with Lower Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients

By MedXY|Feb 4, 2026

This real-world study demonstrates that GLP-1 receptor agonists significantly reduce AF recurrence, progression to permanent AF, and cardiovascular hospitalizations in obese patients following catheter ablation, highlighting their role as a

Challenging Public Health Dogma: Six Months of Low Sweet Taste Exposure Fails to Shift Preference or Weight
Diabetes & EndocrinologyobesityRCT

Challenging Public Health Dogma: Six Months of Low Sweet Taste Exposure Fails to Shift Preference or Weight

By MedXY|Feb 4, 2026

The Sweet Tooth Trial reveals that reducing dietary sweet exposure for six months does not decrease sweet taste liking, calorie intake, or weight, questioning the efficacy of current public health strategies centered solely on reducing swee

Beyond Weight Loss: CagriSema Emerges as a Potent Antihypertensive in Obesity Management
CardiologyCagriSemaGLP-1 RA

Beyond Weight Loss: CagriSema Emerges as a Potent Antihypertensive in Obesity Management

By MedXY|Feb 2, 2026

The REDEFINE 1 trial demonstrates that CagriSema, a semaglutide/cagrilintide combination, significantly reduces blood pressure in adults with overweight or obesity, even among those with resistant hypertension, while facilitating the reduct

Keto vs. Mediterranean: New Evidence on Which Diet Wins for Heart and Brain Health
Cardiologycardiovascular healthmental health

Keto vs. Mediterranean: New Evidence on Which Diet Wins for Heart and Brain Health

By MedXY|Jan 20, 2026

This article compares the Ketogenic and Mediterranean diets’ impact on cardiovascular markers and mental health, highlighting results from two recent pilot studies on blood pressure and the gut-brain axis.

Frontiers in Cardiometabolic Medicine: From Oral GLP-1 Small Molecules to RNAi Therapeutics
Clinical Updatesclinical trialsGLP-1

Frontiers in Cardiometabolic Medicine: From Oral GLP-1 Small Molecules to RNAi Therapeutics

By MedXY|Jan 17, 2026

This review synthesizes recent breakthroughs in obesity, type 2 diabetes, and lipidology, focusing on oral orforglipron, zodasiran for HoFH, and adolescent metabolic risk factors.

Weekly Semaglutide 2.4 mg Delivers 16% Weight Loss in Asian Adults with BMI ≥25: Results from the STEP 11 Phase 3 Trial
Diabetes & Endocrinologyobesitysemaglutide

Weekly Semaglutide 2.4 mg Delivers 16% Weight Loss in Asian Adults with BMI ≥25: Results from the STEP 11 Phase 3 Trial

By MedXY|Jan 15, 2026

The STEP 11 trial demonstrates that once-weekly semaglutide 2.4 mg significantly reduces bodyweight by 16% in Asian adults with obesity (BMI ≥25 kg/m2), providing robust evidence for population-specific clinical guidelines and reimbursement

Multiomics Outperform Phenotype in Predicting Post-Diet Weight Regain and Body Composition Dynamics
Diabetes & Endocrinologygut microbiomeMultiomics

Multiomics Outperform Phenotype in Predicting Post-Diet Weight Regain and Body Composition Dynamics

By MedXY|Dec 31, 2025

A post hoc analysis of the LEAN-TIME trial reveals that integrating gut microbiome and metabolomic data with clinical phenotypes significantly improves the prediction of weight loss and regain, offering a framework for precision weight mana

Tirzepatide Shows Unprecedented Weight Loss and Reduced Insulin Demand in Adults with Type 1 Diabetes and Obesity
Diabetes & Endocrinologyinsulin sensitivityobesity

Tirzepatide Shows Unprecedented Weight Loss and Reduced Insulin Demand in Adults with Type 1 Diabetes and Obesity

By MedXY|Dec 30, 2025

A Phase 2 trial demonstrates that tirzepatide significantly reduces body weight, HbA1c, and total daily insulin requirements in adults with type 1 diabetes and obesity, offering a promising therapeutic strategy for managing metabolic health

Kidney Replacement Therapy Independently Predicts 90-Day Mortality in Critically Ill Patients with Obesity: A 15-Year Trend Analysis
Critical Carecritical careNephrology

Kidney Replacement Therapy Independently Predicts 90-Day Mortality in Critically Ill Patients with Obesity: A 15-Year Trend Analysis

By MedXY|Dec 30, 2025

A 15-year cohort study reveals that obese ICU patients requiring kidney replacement therapy face nearly triple the mortality rate of those who do not, despite a declining trend in overall acute kidney injury incidence within this high-risk

Beyond Congestion: The Wet-Cold Phenotype Drives Mortality in Obese HFpEF
Cardiologycardiac indexhemodynamics

Beyond Congestion: The Wet-Cold Phenotype Drives Mortality in Obese HFpEF

By MedXY|Dec 29, 2025

A hemodynamic study of 227 HFpEF patients reveals that 34% exhibit a low-output phenotype. This cold status, especially when combined with congestion, significantly increases mortality risk in overweight and obese individuals, highlighting

Norepinephrine at Extubation: Challenging the Hemodynamic Safety Paradigm in Critically Ill Patients with Obesity
Anesthesiologycritical careExtubation

Norepinephrine at Extubation: Challenging the Hemodynamic Safety Paradigm in Critically Ill Patients with Obesity

By MedXY|Dec 28, 2025

A multicenter validation study confirms that low-dose norepinephrine at the time of extubation does not increase reintubation rates in patients with obesity, offering clinicians greater flexibility in weaning strategies for hemodynamically

Rethinking Biomarker Thresholds: Why Current NT-proBNP Cutoffs Fail Patients with Obesity and HFpEF
CardiologyHFpEFNT-proBNP

Rethinking Biomarker Thresholds: Why Current NT-proBNP Cutoffs Fail Patients with Obesity and HFpEF

By MedXY|Dec 26, 2025

A pooled analysis of 14,750 patients reveals that current fixed NT-proBNP thresholds significantly underestimate cardiovascular risk in obese patients with heart failure, suggesting a critical need for BMI-adjusted diagnostic and trial elig

High BMI, High Benefit: How PCSK9 Inhibition Optimizes Outcomes in Obese Patients with ASCVD
CardiologyASCVDEvolocumab

High BMI, High Benefit: How PCSK9 Inhibition Optimizes Outcomes in Obese Patients with ASCVD

By MedXY|Dec 25, 2025

A prespecified analysis of the FOURIER trial reveals that patients with obesity and atherosclerotic cardiovascular disease experience significantly higher absolute and relative risk reductions with evolocumab, particularly those with a BMI

Beyond MACE: Semaglutide Significantly Reduces Hospitalization Burden in Patients with Obesity and Cardiovascular Disease
Cardiologycardiovascular diseasehospitalization

Beyond MACE: Semaglutide Significantly Reduces Hospitalization Burden in Patients with Obesity and Cardiovascular Disease

By MedXY|Dec 23, 2025

This exploratory analysis of the SELECT trial demonstrates that semaglutide 2.4 mg reduces total hospital admissions and total days spent in the hospital by approximately 10-11% in patients with established cardiovascular disease and obesit

Diabetes, Obesity, and Early Rhythm Control in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial
Cardiologyatrial fibrillationcardiovascular outcomes

Diabetes, Obesity, and Early Rhythm Control in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial

By MedXY|Dec 22, 2025

This analysis of the EAST-AFNET 4 trial highlights that early rhythm control therapy’s cardiovascular benefits and safety are consistent regardless of diabetes or obesity status in atrial fibrillation patients.

Tirzepatide Lowers 10‑Year Predicted Risk of Cardiovascular Disease and Type 2 Diabetes in Adults with Obesity and Prediabetes: Post hoc Analysis of SURMOUNT‑1
Cardiologycardiometabolic riskobesity

Tirzepatide Lowers 10‑Year Predicted Risk of Cardiovascular Disease and Type 2 Diabetes in Adults with Obesity and Prediabetes: Post hoc Analysis of SURMOUNT‑1

By MedXY|Dec 5, 2025

A post hoc analysis of the three‑year SURMOUNT‑1 trial found that once‑weekly tirzepatide (5–15 mg) produced dose‑dependent reductions in 10‑year predicted risks for ASCVD, heart failure, total CVD and progression to type 2 diabetes versus

Orforglipron in Type 2 Diabetes and Obesity: A Promising Oral GLP‑1 Agonist That Delivers Clinically Meaningful Weight and Glycaemic Benefits
Diabetes & EndocrinologyGLP-1 receptor agonistobesity

Orforglipron in Type 2 Diabetes and Obesity: A Promising Oral GLP‑1 Agonist That Delivers Clinically Meaningful Weight and Glycaemic Benefits

By MedXY|Nov 28, 2025

In ATTAIN‑2, oral orforglipron produced dose‑dependent, statistically superior weight loss and improved HbA1c versus placebo over 72 weeks in adults with overweight/obesity and type 2 diabetes, with an adverse‑event profile dominated by gas

Metformin Fails to Delay Progression on Active Surveillance for Low‑Risk Prostate Cancer — Unexpected Signal in Obese Men
newsactive surveillancemetformin

Metformin Fails to Delay Progression on Active Surveillance for Low‑Risk Prostate Cancer — Unexpected Signal in Obese Men

By MedXY|Nov 23, 2025

The MAST phase III trial found no benefit of metformin (850 mg twice daily) versus placebo for delaying progression in men with low‑risk prostate cancer on active surveillance; a prespecified subgroup showed increased pathologic progression

Prev
3 / 7
12345…7
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities